最新发布
Myca raises $1.3m pre-seed to put AI agents in charge of agribusiness field operations
Myca, best known for its AI agents that coordinate agribusiness field teams, has raised $1.3 million in pre-seed funding…
Argenx halts Phase 3 Sjögren’s trial, sending shares tumbling
Why it matters: The setback closes off the current pivotal development path for expanding Vyvgart into another autoimmune disease. It also reverses encouraging early findings in Sjögren’s, although the company reported no new safety signals.
Nigeria Launches AgriConnect Compact To Scale Digital Agriculture And Mobilise $5bn
36 Nigeria has launched the AgriConnect Compact, a five-year agricultural transformation initiative targeting nearly 3 m…
🎥 Can Picker AgRobotics’ Dr Octopus-style arms finally crack autonomous fruit harvesting?
Can robots inspired by elephant trunks finally crack the economics of autonomous fruit harvesting? While other orchard r…
Rivercell raises $25M to build an AI virtual cell
Who’s investing: German investor HV Capital led the round, with participation from HCVC, Alven and Bpifrance Digital Venture. The financing will support Rivercell’s data generation platform, expansion of its automated wet lab in Paris and development of its AI Virtual Cell program.
Report: Europe’s biotech leaders see recovery, but investors remain the obstacle
The European breakdown covers companies headquartered in the EU/EEA, the UK and Switzerland. It separates their responses from the global survey of 81 executives being released by the organizers.
Forbion raises record-breaking €2.3B to back 30 biotechs
Why it matters: The capital will support both new drug developers and companies facing the cost of clinical development. Forbion’s success comes as European investors push to deepen the pools of money available to build and scale biotechs.
Sensible secures $47M to rethink mRNA manufacturing
Who’s backing it: The round was led by Oxford Science Enterprises. New investors OTB Ventures and In-Q-Tel joined existing backers, including Recode Ventures, Isomer Capital, Y Combinator, Backed VC, Kaya VC, Civilization Ventures and BlueYard Capital. The family office of BioNTech co-founder Christoph Huber and former Eli Lilly chief medical officer Tim Garnett also participated.
RougeTx launches with $58M to tackle rare bleeding disorder
Why it matters: There are currently no therapies approved specifically for HHT. The inherited disease causes abnormal connections between arteries and veins – arteriovenous malformations (AVMs) – which can result in recurrent nose and gastrointestinal bleeding, anemia, and complications in the lungs, liver, and brain.
Genmab and AbbVie’s bispecific antibody halves progression-or-death risk in lymphoma trial
Why it matters: The companies call EPCORE DLBCL-2 the first Phase 3 trial of a bispecific antibody combination to significantly improve progression-free survival (PFS) — how long patients live without their lymphoma worsening — in newly diagnosed DLBCL. A frontline label would move epcoritamab — authorized in the EU as monotherapy for relapsed or refractory DLBCL after two or more lines of systemic therapy — into a setting where Roche’s antibody-drug conjugate Polivy has been approved since 2022.